Investor FAQ 

🪖 Mission Alignment

Q: Why should veterans invest in Clearikon™?
A: You know firsthand the challenges of combat casualty care. ClearikonFLEX™ directly addresses those pain points—reducing unnecessary bandage changes, lowering infection risk, and multiplying caregiver capacity. Your investment helps bring battlefield-ready innovation to the people who need it most.

⚔️ Battlefield Readiness

Q: Will this technology truly hold up in combat conditions?
A: Yes. ClearikonFLEX™ is engineered for rugged environments—resistant to dirt, sweat, water, and extreme temperatures. It’s designed with the realities of combat in mind, not just hospital settings.

🎖️ Differentiation & Advantage

Q: How is this different from what medics already carry?
A: Unlike opaque trauma dressings, ClearikonFLEX™ enables continuous wound visibility and monitoring. This means fewer dressing changes, faster triage, and better outcomes—an advantage that veterans understand translates to saved lives and reduced costs.

💰 Investment Opportunity

Q: What’s the market potential for investors?
A: Clearikon™ is targeting four high-value markets—Military, Hospital, Home Health, and Veterinary—together worth over $16B globally. Military adoption alone represents a $5.77B opportunity by 2025. Early revenue is expected in 2026, with scalable manufacturing already in place.

📋 Regulatory & Reimbursement Pathway

Q: How do you overcome regulatory hurdles?
A: ClearikonFLEX™ is a Class I medical device—low risk, non-invasive, with a 2-day FDA notification pathway. No 510(k) required. Our advisors also anticipate a unique CPT code, enabling direct billing and strong reimbursement potential.

Q: What are the FDA clearance pathways?
A: 510(k) Process (Class II & some Class I devices):

• Companies demonstrate their device is “substantially equivalent” to a legally marketed predicate device.

• Submission includes technical data, performance testing, and sometimes limited clinical evidence.

• FDA review typically takes months, offering a faster, lower‑cost route compared to full Premarket Approval (PMA).

• Outcome: FDA issues a clearance letter, allowing U.S. commercialization.

Class I Devices – Notification/Exemption:

• Many low‑risk Class I devices (e.g., bandages, stethoscopes, tongue depressors) are exempt from 510(k) requirements.

• Instead, manufacturers must register their establishment and list their devices with the FDA.

• No formal clearance letter is issued; compliance focuses on general controls such as proper labeling, good manufacturing practices, and adverse event reporting.

• For investors, this means minimal regulatory burden and rapid market entry, though companies must still maintain FDA compliance infrastructure.

Q: What are CPT codes

A: CPT (Current Procedural Terminology) codes are five-digit numeric codes developed and maintained by the American Medical Association (AMA) to describe medical, surgical, and diagnostic services performed by healthcare professionals. They are used universally for billing purposes by healthcare providers, government payers, and private insurers. CPT codes are divided into three categories: Category I for standard procedures, Category II for performance measurement, and Category III for emerging technologies

Q:What are HCPCS codes?

A:HCPCS (Healthcare Common Procedure Coding System) codes are alphanumeric and are used to report medical procedures and services to Medicare, Medicaid, and other health insurance programs. HCPCS includes two primary levels: Level I, which is identical to CPT codes (also known as CPT-4), and Level II, which covers products, supplies, and services not included in CPT codes, such as durable medical equipment, ambulance services, and certain drugs. 

Level II codes are maintained by the Centers for Medicare and Medicaid Services (CMS) and are in the public domain, unlike CPT codes, which are copyrighted by the AMA. The key difference lies in their scope, with CPT focusing on procedures and HCPCS, particularly Level II, covering non-physician services and supplies.

🧪 Proof & Validation

Q: Is there evidence this reduces infection risk?
A: Clinical advisors and early trials confirm fewer dressing changes correlate with lower infection rates. We are expanding validation with military and hospital partners to strengthen adoption.

📡 Future Growth

Q: What’s next beyond the current bandage?
A: Our smart trauma bandage, ClearikonSYNC™ is in development—continuously monitoring wounds, storing data offline, and communicating status to medics. This positions Clearikon™ for leadership in precision wound care and digital health integration.

🇺🇸 Veteran Impact

Q: How does investing make a difference for service members?
A: Your investment accelerates deployment of technology that directly supports wounded warriors in austere environments. It’s not just financial return—it’s mission-driven impact that veterans can be proud to back.